Study On Patient Support Program Impact Piques EMA's Interest
Executive Summary
The pharmaceutical industry's renewed effort to find a pragmatic solution to managing adverse events from patient support programs has drawn the European Medicines Agency's attention.
You may also be interested in...
ICH Makes Progress On Tackling Safety Data ‘Overload’
Changes to an ICH guideline could help drug companies that are being deluged with post-approval safety information to cut down on noisy, low-value data.
EMA To Update Active Substances Guide To Address Nitrosamine Contamination
The European Medicines Agency wants to make it clearer for drug sponsors what more they can do to address the presence of cancer-causing impurities in active substances, and how to deal with the issue in their regulatory submissions.
EMA Tackles Delays With Scientific Advice Procedure
A surge in scientific advice requests in the latter half of 2021 forced the European Medicines Agency to delay the start of some procedures, but the situation has improved considerably since then.